

## ART / Infertility / Gender Dysphoria

Bravelle (urofollitropin)

Cetrotide (cetorelix)

Clomiphene citrate, Clomiphene powder

Crinone, Endometrin, Progesterone in oil, Progesterone powder, Prometrium (progesterone)

Follistim AQ (follitropin beta)

Fyremadel/Ganirelix (ganirelix)

Gonal-F, Gonal-F RFF (follitropin alfa)

Menopur (menotropins)

Milprosa\* (progesterone)

\*This medication is included in this policy but is not available on the market as of yet

## Pre - PA Allowance

*The drugs addressed by this policy are covered without a Prior Authorization (PA) for all female patients over 50 years of age.*

---

## Prior-Approval Requirements

*The drugs addressed by this policy are covered without a Prior Authorization (PA) for all female patients over 50 years of age.*

### Diagnoses

#### Female

**ALL** diagnoses are covered **EXCEPT**:

Patients must **NOT** use for the following indication:

1. Used in conjunction with assisted reproductive technology (ART) procedures, which include but are not limited to:
  - a. Artificial insemination (AI)
  - b. In vitro fertilization (IVF)
  - c. Embryo transfer and gamete intrafallopian transfer (GIFT)
  - d. Zygote intrafallopian transfer (ZIFT)
  - e. Intravaginal insemination (IVI)
  - f. Intracervical insemination (ICI)
  - g. Intracytoplasmic sperm injection (ICSI)
  - h. Intrauterine insemination (IUI)

#### Male

**ALL** diagnoses are covered **EXCEPT**:

For the following indication patient must have:

1. Hypogonadotropic hypogonadism with **ALL** of the following:



## **ART / Infertility / Gender Dysphoria**

Bravelle (urofollitropin)

Cetrotide (cetorelix)

Clomiphene citrate, Clomiphene powder

Crinone, Endometrin, Progesterone in oil, Progesterone powder, Prometrium (progesterone)

Follistim AQ (follitropin beta)

Fyremadel/Ganirelix (ganirelix)

Gonal-F, Gonal-F RFF (follitropin alfa)

Menopur (menotropins)

Milprosa\* (progesterone)

\*This medication is included in this policy but is not available on the market as of yet

- a. **NOT** caused by primary testicular failure
- b. Patient has low pretreatment testosterone levels
- c. Patient has low or low-normal follicle stimulating hormone (FSH) or luteinizing hormone (LH) levels
- d. Used for spermatogenesis

**AND NOT** used for the following for both males and females:

- 1. Weight loss
- 2. Anti-aging effects
- 3. Performance (athletic) enhancement
- 4. Erectile or sexual dysfunction

### **Diagnosis**

The patient must have the following:

Gender Dysphoria (GD)

- 1. Prescribed by an endocrinologist or transgender specialist
- 2. Patient has met the DSM V criteria for GD

### **Prior - Approval Limits**

|                 |         |           |
|-----------------|---------|-----------|
| <b>Duration</b> | Females | 6 months  |
|                 | Males   | 12 months |
|                 | GD      | 2 years   |

### **Prior – Approval *Renewal* Requirements**

*The drugs addressed by this policy are covered without a Prior Authorization (PA) for all female patients over 50 years of age.*



## **ART / Infertility / Gender Dysphoria**

Bravelle (urofollitropin)

Cetrotide (cetorelix)

Clomiphene citrate, Clomiphene powder

Crinone, Endometrin, Progesterone in oil, Progesterone powder, Prometrium (progesterone)

Follistim AQ (follitropin beta)

Fyremadel/Ganirelix (ganirelix)

Gonal-F, Gonal-F RFF (follitropin alfa)

Menopur (menotropins)

Milprosa\* (progesterone)

\*This medication is included in this policy but is not available on the market as of yet

### **Diagnoses**

#### **Female**

**ALL** diagnoses are covered **EXCEPT:**

Patients must **NOT** use for the following indication:

1. Use in conjunction with assisted reproductive technology (ART) procedures, which include but are not limited to:
  - a. Artificial insemination (AI)
  - b. In vitro fertilization (IVF)
  - c. Embryo transfer and gamete intrafallopian transfer (GIFT)
  - d. Zygote intrafallopian transfer (ZIFT)
  - e. Intravaginal insemination (IVI)
  - f. Intracervical insemination (ICI)
  - g. Intracytoplasmic sperm injection (ICSI)
  - h. Intrauterine insemination (IUI)

#### **Male**

**ALL** diagnoses are covered **EXCEPT:**

For the following indication patient must have:

1. Hypogonadotropic hypogonadism with **ALL** of the following:
  - a. **NOT** caused by primary testicular failure
  - b. Patient has low pretreatment testosterone levels
  - c. Patient has low or low-normal follicle stimulating hormone (FSH) or luteinizing hormone (LH) levels
  - d. Used for spermatogenesis

**AND NOT** used for the following for both males and females:

1. Weight loss
2. Anti-aging effects

**ART / Infertility / Gender Dysphoria**

Bravelle (urofollitropin)

Cetrotide (cetorelix)

Clomiphene citrate, Clomiphene powder

Crinone, Endometrin, Progesterone in oil, Progesterone powder, Prometrium (progesterone)

Follistim AQ (follitropin beta)

Fyremadel/Ganirelix (ganirelix)

Gonal-F, Gonal-F RFF (follitropin alfa)

Menopur (menotropins)

Milprosa\* (progesterone)

\*This medication is included in this policy but is not available on the market as of yet

3. Performance (athletic) enhancement
4. Erectile or sexual dysfunction

---

**Diagnosis**

The patient must have the following:

Gender Dysphoria (GD)

1. Prescribed by an endocrinologist or transgender specialist

**Prior - Approval *Renewal* Limits**

Same as above